| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
It is known that children with Down syndrome are at about 10-20 times higher risk of leukemia than healthy children. About 10% of newborns with Down Syndrome develop a blood disease (TAM) in which immature megakaryocytes transiently proliferate, and about 20% of them progresses to megakaryocytic leukemia (ML-DS). The purpose of this study is to clarify the molecular mechanism for deveplopment of ML-DS.
In almost of all TAM and ML-DS, mutations of the megakaryocytic transcription factor GATA1 are detected. In this study, we revealed that GATA1 mutations affected the expression control of KIT gene which supports cell survival and proliferation. And, about the reserch of cohesin complex whose gene mutations are detected with high frequency in ML-DS, we are now investigating the effect on regulation of gene expression.
|
